Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple RNA test predict pancreatic cancer outcomes?

NCT ID NCT04765410

Knowledge-focused Sponsor: Carol Davila University of Medicine and Pharmacy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined small RNA molecules called microRNAs in tissue samples from 57 people with pancreatic cancer. The samples were collected during a routine endoscopic ultrasound procedure. Researchers aimed to see if certain microRNA patterns are linked to how aggressive the cancer is, how long patients live, and how they respond to treatment. The goal is to eventually use this information to personalize care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

57 people

The number who actually took part.

Started

Mar 2019

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pancreatic solid mass, with or without a cystic component * Age over 18 years old * Signed informed consent Exclusion Criteria: * Cystic pancreatic mass with no solid component * Abnormal coagulation (elevated INR \>1.5, thrombocytopenia\<60 000/mm3, activated partial thromboplastin time\>42 seconds), participant on anticoagulant treatment that cannot stop the treatment * European Cooperative Oncology Group status 4 * Pregnancy * Age under 18 years old * The participant does not want to sign the consent form, or is unable to * Difficult puncture position during endoscopic ultrasonography: vessels or Wirsung duct positioned in front of the needle (decision of the endoscopist)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic adenocarcinoma

Contacts and locations

Locations

  • "Carol Davila" University Central Emergency Hospital

    Bucharest, Sector 1, 010825, Romania

  • "Prof Dr Agrippa Ionescu" Emergency Hospital

    Bucharest, Sector 1, 011356, Romania

  • "Victor Babes" National Pathology Institute

    Bucharest, Sector, 050096, Romania

  • Clinical Emergency Hospital Bucharest

    Bucharest, Sector 1, 014461, Romania

  • Fundeni Clinical Institute

    Bucharest, Sector 2, 022328, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.